Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment

An expert discusses emerging developments in the use of systemic immunotherapy for recurrent/metastatic nasopharyngeal carcinoma (NPC) from the perspective of a radiation oncologist, highlighting how findings from Liu et al (Lancet, 2024) inform the evolving treatment landscape.

EP: 1.Introduction to Clinical Cases: Toripalimab in Recurrent and Metastatic NPC

EP: 2.Considerations for NPC Therapy: Clinical Perspectives From Radiation Oncology

EP: 3.Targeting Recurrent and Metastatic NPC With Systemic Immunotherapy: The Role of Toripalimab and Insights From Radiation Oncology

EP: 4.Monitoring Treatment Response in NPC: Looking to EBV Titers and Imaging

Now Viewing

EP: 5.Evolving Paradigms: The Role of Systemic Immunotherapy in NPC Treatment

Video content above is prompted by the following:

• With emerging developments in the use of systemic immunotherapy for recurrent/metastatic NPC, what insights can you share from the perspective of a radiation oncologist?
• How do findings from inform the treatment landscape?

Recent Videos